{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"}]}],"title":"Grade 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}],"title":"Grade 4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}],"title":"Grade 5"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"4"}],"units":"Participants"}],"description":"The maximum grade of each type of toxicity will be recorded for each patient. For each toxicity reported by dose level, the percentage of patients developing any degree of that toxicity as well as the percentage of patients developing a severe degree (Grade 3 or higher) will be determined. Adverse Events were graded using CTCAE v4.0.","groups":[{"description":"Ibrutinib 560 mg on Days 1-28,\n\n\\> Lenalidomide 15 mg on Days 1-21 Dexamethasone 40 mg on Days 1,8,15, 22\n\n\\>\n\n\\> Every 28 days","id":"OG000","title":"Dose Level 1 Starting Cohort"},{"description":"Ibrutinib 560 mg on Days 1-28,\n\n\\> Lenalidomide 25 mg on Days 1-21 Dexamethasone 40 mg on Days 1,8,15, 22\n\n\\>\n\n\\> Every 28 days","id":"OG001","title":"Dose Level 2"},{"description":"Ibrutinib 840 mg on Days 1-28,\n\n\\> Lenalidomide 25 mg on Days 1-21 Dexamethasone 40 mg on Days 1,8,15, 22\n\n\\>\n\n\\> Every 28 days","id":"OG002","title":"Dose Level 3"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All eligible patients who began protocol treatment.","reportingStatus":"POSTED","timeFrame":"Up to 34 month","title":"Maximum Toxicity Grade","type":"PRIMARY","unitOfMeasure":"Participants"}